Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedJun 05, 2026
DataAggregated Company Financials
Companies55
  • 7D1.0%
  • 3M22.1%
  • 1Y68.6%
  • YTD5.6%

In the last week, the Pharma industry is up 1.0%, with Curaleaf Holdings up 3.7%. This takes the industry's 12 month performance to a gain of 69%. Looking forward, earnings are forecast to grow by 32% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 05 Jun 2026CA$16.2bCA$12.2b-CA$1,905,005,328.098.6x-8.5x1.3x
Sun, 03 May 2026CA$16.9bCA$11.2b-CA$1,662,033,028.7315.4x-10.2x1.5x
Tue, 31 Mar 2026CA$12.7bCA$11.4b-CA$1,689,146,352.3911.8x-7.5x1.1x
Thu, 26 Feb 2026CA$14.7bCA$11.2b-CA$1,902,451,257.9214.6x-7.7x1.3x
Sat, 24 Jan 2026CA$16.2bCA$11.2b-CA$1,938,988,736.7116.3x-8.3x1.4x
Mon, 22 Dec 2025CA$17.0bCA$11.3b-CA$1,947,832,753.5114.8x-8.7x1.5x
Wed, 19 Nov 2025CA$12.8bCA$11.3b-CA$1,918,840,197.9714.7x-6.7x1.1x
Fri, 17 Oct 2025CA$18.3bCA$11.3b-CA$2,046,181,421.9635.6x-9x1.6x
Sun, 14 Sep 2025CA$15.3bCA$11.2b-CA$2,034,635,474.5240.3x-7.5x1.4x
Tue, 12 Aug 2025CA$13.6bCA$11.7b-CA$2,533,797,497.3522.8x-5.4x1.2x
Thu, 10 Jul 2025CA$10.5bCA$11.7b-CA$2,541,044,068.9119.2x-4.1x0.9x
Sat, 07 Jun 2025CA$9.5bCA$11.7b-CA$2,523,071,804.7118x-3.8x0.8x
Mon, 05 May 2025CA$10.8bCA$11.9b-CA$2,504,572,218.8420.9x-4.3x0.9x
Wed, 02 Apr 2025CA$10.3bCA$12.3b-CA$2,631,360,614.3619.4x-3.9x0.8x
Fri, 28 Feb 2025CA$11.5bCA$12.3b-CA$2,223,991,819.0622.2x-5.2x0.9x
Sun, 26 Jan 2025CA$12.1bCA$12.1b-CA$2,410,157,394.2135.6x-5x1x
Tue, 24 Dec 2024CA$12.7bCA$12.1b-CA$2,414,726,587.7422.8x-5.3x1x
Thu, 21 Nov 2024CA$14.3bCA$12.0b-CA$2,672,739,880.9317x-5.3x1.2x
Sat, 19 Oct 2024CA$19.0bCA$11.8b-CA$2,708,707,823.9617.4x-7x1.6x
Mon, 16 Sep 2024CA$18.1bCA$11.6b-CA$2,703,089,761.5120.7x-6.7x1.6x
Wed, 14 Aug 2024CA$18.6bCA$11.7b-CA$2,767,314,339.1722.5x-6.7x1.6x
Fri, 12 Jul 2024CA$18.7bCA$11.7b-CA$3,179,115,064.6619.7x-5.9x1.6x
Sun, 09 Jun 2024CA$20.8bCA$11.8b-CA$2,756,296,099.6812.8x-7.5x1.8x
Tue, 07 May 2024CA$24.2bCA$11.8b-CA$3,417,258,262.8310.9x-7.1x2x
Thu, 04 Apr 2024CA$20.9bCA$10.4b-CA$3,522,094,811.729x-5.9x2x
Sat, 02 Mar 2024CA$21.0bCA$12.0b-CA$4,470,416,386.149.4x-4.7x1.8x
Mon, 29 Jan 2024CA$22.3bCA$12.3b-CA$6,748,442,370.009.6x-3.3x1.8x
Wed, 27 Dec 2023CA$17.1bCA$12.2b-CA$6,713,748,928.008.6x-2.5x1.4x
Fri, 24 Nov 2023CA$18.3bCA$12.5b-CA$6,838,777,984.007.1x-2.7x1.5x
Sun, 22 Oct 2023CA$17.3bCA$12.4b-CA$7,341,920,600.0012x-2.4x1.4x
Tue, 19 Sep 2023CA$22.3bCA$13.0b-CA$7,885,143,211.0014.6x-2.8x1.7x
Thu, 17 Aug 2023CA$13.7bCA$13.0b-CA$8,070,709,387.0010.8x-1.7x1.1x
Sat, 15 Jul 2023CA$15.9bCA$13.2b-CA$9,718,923,315.0012.4x-1.6x1.2x
Mon, 12 Jun 2023CA$14.8bCA$13.2b-CA$10,391,543,924.0010.4x-1.4x1.1x
Price to Earnings Ratio

-1.4x


Total Market Cap: CA$14.8bTotal Earnings: -CA$10,391,543,924.00Total Revenue: CA$13.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 2.7% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market1.83%
Healthcare0.72%
Pharma1.03%
Pharma1.03%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CURA Curaleaf HoldingsCA$15.213.7%
+CA$427.9m		329.7%PS6.7x
TRUL Trulieve CannabisCA$13.813.2%
+CA$81.7m		155.6%PS1.6x
GTII Green Thumb IndustriesCA$11.312.6%
+CA$63.5m		61.6%PE14.7x
GUD Knight TherapeuticsCA$8.466.4%
+CA$50.1m		40.5%PE148.1x
NVRS Noveris Health SciencesCA$2.7532.2%
+CA$39.2m		450.0%PE100.4x

Latest News

TRUL
CA$13.81
Trulieve Cannabis
7D
3.2%
1Y
155.6%
VREO
CA$17.40
Vireo Growth
7D
-3.3%
1Y
9.4%
CURA
CA$15.21
Curaleaf Holdings
7D
3.7%
1Y
329.7%
CRDL
CA$1.61
Cardiol Therapeutics
7D
-10.1%
1Y
-13.9%
Analysis Article • Jun 04

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
WEED
CA$1.47
Canopy Growth
7D
-4.5%
1Y
-21.0%
Narrative Update • Jun 04

WEED: German Medical Relaunch And New Brand Portfolio Will Drive Upside

Analysts have adjusted their price target for Canopy Growth to CA$4.82, with updated assumptions that include a slightly higher discount rate, modestly different revenue growth expectations, a small change in projected profit margin and a revised future P/E estimate. What's in the News Relaunch of the Tweed brand in the German medical cannabis market, with three initial strains supplied by wholly owned subsidiary MTL Cannabis Corp., targeting physicians and patients familiar with the legacy brand.
CL
CA$1.27
Cresco Labs
7D
-3.8%
1Y
76.4%
Narrative Update • Jun 04

CL: Expanded Footprint And Texas License Will Support A More Upside Skewed Profile

Analysts trimmed their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E that together support a slightly lower fair value estimate. What's in the News Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second new Ohio dispensary in the past month, bringing the footprint to eight locations in the state and 74 nationally.
CWEB
CA$0.57
Charlotte's Web Holdings
7D
-18.6%
1Y
322.2%
QNTM
CA$6.24
Quantum BioPharma
7D
-36.0%
1Y
-66.5%
VRNO
CA$1.51
Verano Holdings
7D
-6.2%
1Y
112.7%
Narrative Update • Jun 01

VRNO: Federal Reform Timing Will Drive Repricing As DEA Registrations Advance

Analysts now center their CA$5.00 price target for Verano Holdings on mixed research updates that balance broadly in-line Q4 sales and EBITDA with continued uncertainty around the timing of U.S. federal reform. Analyst Commentary Recent Street commentary centers on a CA$5.00 price target, with mixed signals around risk and reward.
GUD
CA$8.46
Knight Therapeutics
7D
6.4%
1Y
40.5%
GTII
CA$11.31
Green Thumb Industries
7D
2.6%
1Y
61.6%
Narrative Update • May 28

GTII: Partial Cannabis Rescheduling Will Support Re Rating Despite Medical Efficacy Concerns

Analysts have increased their CA$ price target on Green Thumb Industries by CA$4.17 to reflect updated fair value assumptions and a higher future P/E multiple, following recent research that highlights both a raised Benchmark target and Roth's view that partial cannabis rescheduling is extremely favorable for the sector. Analyst Commentary Bullish analysts are framing the latest research on Green Thumb Industries around two key themes: updated valuation work and a more supportive regulatory backdrop for cannabis.
CPH
CA$16.75
Cipher Pharmaceuticals
7D
1.5%
1Y
36.6%
Narrative Update • May 22

CPH: Share Repurchases And Higher Conviction Forecasts Will Support Future Upside

Analysts have lifted their price target on Cipher Pharmaceuticals to CA$22 from CA$21, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in recent research. Analyst Commentary Bullish Takeaways Bullish analysts are signaling higher conviction in Cipher Pharmaceuticals' valuation by moving the price target from CA$20 to CA$22 within recent research updates.
NVRS
CA$2.75
Noveris Health Sciences
7D
32.2%
1Y
450.0%
XLY
CA$0.17
Auxly Cannabis Group
7D
13.3%
1Y
112.5%
GRIN
CA$0.60
Grown Rogue International
7D
5.3%
1Y
30.4%
IAN
CA$0.005
iAnthus Capital Holdings
7D
-50.0%
1Y
0%